PharmaNews.eu
  • Home
  • Business
  • R&D
  • EC
  • EMA
  • Events
  • Open Calls

Lundbeck

Lundbeck

LundbeckH. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is an international pharmaceutical company highly committed to improving the quality of life for people suffering from brain disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company's products are targeted at disorders such as depression and anxiety, psychotic disorders, epilepsy and Huntington's, Alzheimer's and Parkinson's diseases.

Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark. Today Lundbeck employs approximately 6,000 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with brain disorders. In 2011, the company's revenue was DKK 16.0 billion (approximately EUR 2.1 billion or USD 3.0 billion). For more information, please visit www.lundbeck.com.

Lundbeck RSS Channel

Filters
List of articles in category Lundbeck
Title Published Date
Lundbeck appeals European Commission decision 02 September 2013
Lundbeck files for regulatory approval of the novel multimodal antidepressant, vortioxetine 20 September 2012
Lundbeck disagrees with the Statement of Objections issued by the European Commission 27 July 2012
Lundbeck plans to establish a more flexible commercial organisation in Europe 14 June 2012
  1. You are here:  
  2. Home
  3. Lundbeck

About

  • Home
  • Terms and Conditions
  • Contact

Advertise

Top News Channels

  • Business
  • Research
  • EMA
  • Events

Follow us

Didn't we got you connected? If not, please note the following magic buttons:

  • Facebook
  • Twitter
  • RSS 2.0
  • Atom 1.0

Newsletter

Stay updated on the latest Pharma News. Subscribe now, it's free!

Copyright © 2025 PharmaNews.eu. All Rights Reserved.